# Glargine U300 Hospital Trial

Study · id `cardio:ct-nct03013985` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03013985](<https://clinicaltrials.gov/study/NCT03013985>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03013985

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 247 participants.

## Technical summary

Registry record NCT03013985. Randomized; no masking; primary purpose treatment. Start 2017-05-17 (actual); primary completion 2019-03-22 (actual). Results posted on 2020-05-07.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 247 participants (enrolled count; ClinicalTrials.gov record NCT03013985, source copy `cardio:ctgov-nct03013985-2020-05-07`, retrieved 2026-10-26)
- Started: 2017-05-17 (actual) (ClinicalTrials.gov record NCT03013985, source copy `cardio:ctgov-nct03013985-2020-05-07`, retrieved 2026-10-26)
- Primary completion: 2019-03-22 (actual) (ClinicalTrials.gov record NCT03013985, source copy `cardio:ctgov-nct03013985-2020-05-07`, retrieved 2026-10-26)
- Completion: 2019-03-22 (actual) (ClinicalTrials.gov record NCT03013985, source copy `cardio:ctgov-nct03013985-2020-05-07`, retrieved 2026-10-26)
- Results first posted: 2020-05-07 (ClinicalTrials.gov record NCT03013985, source copy `cardio:ctgov-nct03013985-2020-05-07`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03013985, source copy `cardio:ctgov-nct03013985-2020-05-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03013985-2020-05-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glargine U300 Hospital Trial
- Condition: Type 2 Diabetes
- Intervention (Drug): Glargine U300
- Intervention (Drug): Glargine U100
- Intervention (Drug): Glulisine Insulin
- Lead sponsor: Emory University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Emory University (`cardio:org-emory-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial (`cardio:pubmed-32273271`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 958bcf0fda4594807a72d46138cb2e74a18e76af83ee6ad6382a5bafe4c61a3e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
